GSK’s Blenrep combinations have been approved in Japan for treating relapsed or refractory multiple myeloma, following strong Phase III trial results demonstrating improved survival outcomes.
The stepwise vaccination approach successfully activated and matured B cells toward producing broadly neutralizing antibodies, marking a major milestone in the pursuit of an effective HIV vaccine.
In addition, the research showed an 80% reduction in the hospitalization risk of cardiovascular disease in individuals with Type 1 diabetes who did not have a previous history of such illnesses.
EMRELIS™ (telisotuzumab vedotin-tllv) used for previously treated adult patients with advanced non-small cell lung cancer (NSCLC) exhibiting high c-Met protein overexpression.
The APHINITY study’s ten-year follow-up results showed that adjuvant Perjeta® (pertuzumab) added to chemotherapy and Herceptin® (trastuzumab) resulted in a clinically significant survival benefit.
The results are based on the SURMOUNT-5 Phase 3b open-label clinical trial, in which the two incretin-based drugs were directly compared over a 72-week duration.
The Phase III POTOMAC trial evaluated the effectiveness of Imfinzi in combination with BCG therapy compared to BCG therapy alone in patients with high-risk NMIBC.
The computer program forecasts individual strands of DNA building blocks (A, T, C, and G) needed to create desired patterns of gene expression in various types of cells.
One of the most prevalent causes of chronic liver disease in the developed world, MASLD affects about 30% of the population.
Amgen Inc. (NASDAQ: AMGN) announced its financial results for the first quarter ended March 31, 2025, showcasing significant revenue growth fueled by strong product volume [Read More…]
